Hampel looks to the future of the Alzheimer space and sees promise, especially since there’s transfertilization from other advanced science fields in medicine like oncology, diabetes research and rheumatology.
Harald Hampel, MD, PhD, MA, MSc
Advertisement
Articles by Harald Hampel, MD, PhD, MA, MSc
The phase IIb/III study is scheduled to initiate enrollment of approximately 450 patients, randomized 1:1:1 to 2 different ANAVEX 2-73 doses or placebo.
ANAVEX 2-73 is being studied as the first potential precision medicine biomarker-guided, targeted therapeutic in Alzheimer disease.
Advertisement
Latest Updated Articles
Harald Hampel, MD, PhD, MA, MSc: Phase IIa Study of ANAVEX 2-73 in Treatment of Alzheimer DiseasePublished: August 10th 2018 | Updated:
- Harald Hampel, MD, PhD, MA, MSc on Advancements and Challenges in the Alzheimer Space
Published: August 13th 2018 | Updated:
- Harald Hampel, MD, PhD, MA, MSc: Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study
Published: August 4th 2018 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Anti-MTBR Tau Antibody Etalanetug Given FDA Fast Track Designation
2
Smartphone-Based App for Muscular Relaxation Significantly Reduces Migraine-Related Disability in Emergency Room Settings
3
Early Intervention in Myasthenia Gravis
4
MDS Congress 2025: Top Expert Interviews and Key Takeaways
5
